Table 2 Quality of life in 24 CAPS patients at baseline
Patient | Age (years) | Gender | Disease duration to start T0 drug (years) | Druga | Treatment duration (months) | EQ-5D | CHQ-physicalb | CHQ-psycho socialb | AIDAI |
|---|---|---|---|---|---|---|---|---|---|
1001 | 62.6 | M | 26.3 | Cana 150q6w | 51 | 0.296 | 9.7 | ||
1002 | 39.0 | M | UK | Cana 150q6w | 51 | 0.786 | |||
1003 | 59.2 | F | 38.8 | Cana 150q8w | 16 | 0.848 | 4.2 | ||
1004 | 59.2 | F | 0.33 | Cana 150 q8w | 57 | ||||
1005 | 34.7 | F | No | ||||||
1006 | 28.9 | F | UK | Cana 150q8w | 1 | 0.680 | |||
1007 | 61.2 | F | UK | Cana 150q8w | 10 | 0.813 | |||
1008 | 65.0 | M | UK | Cana 150q8w | 76 | 0.533 | 0.0 | ||
1009 | 69.1 | M | UK | Cana 150q8w | 55 | 0.852 | |||
2001 | 24.6 | M | 20.25 | Cana 150q8w | 51 | 0.887 | 0.1 | ||
2002 | 65.8 | M | 41.5 | Cana 150q8w | 51 | 0.695 | |||
2003 | 82.0 | M | 48.4 | Ana 100q1d | 42 | ||||
2004 | 52.0 | F | 39.3 | Cana 300q4w | 56 | 0.848 | 2.8 | ||
2005 | 54.6 | F | UK | Cana 150q10w | 33 | 0.752 | 0.4 | ||
2006 | 5.6 | M | 4.7 | Cana 100q8w | 10 | ||||
2007 | 15.5 | F | 11.4 | Cana 150q10w | 48 | 1.000 | 58.7 | 54.3 | |
2008 | 5.3 | F | 2.1 | Cana 45q8w | 29 | 46.9 | 57.7 | 0.1 | |
2009 | 23.0 | F | No | ||||||
2010 | 8.2 | F | 4.1 | Cana 90q8w | 48 | 49.1 | 59.3 | 0.0 | |
2011 | 8.4 | F | 3.0 | Cana 50q8w | 20 | 52.7 | 61.7 | 0.0 | |
2012 | 16.0 | M | UK | Ana 100q1d | 48 | ||||
2013 | 16.2 | F | 4.7 | Cana 150q10w | 49 | 0.887 | 47.9 | 57.1 | |
2014 | 24.4 | F | 19.1 | Cana 150q8w | 57 | 0.887 | 3.4 | ||
2015 | 23.1 | F | 19.2 | Ana 100q1d | 46 | ||||
Median | 48 | ||||||||
Mean | 0.769 | 51.1 | 57.1 | 2.1 |